Funds
Name Truecaller
Target
Boost international expansion
Investors Open Ocean
Open Ocean invests in Truecaller to help boost international expansion INVESTOR
Open Ocean. Others undisclosed.
TARGET Truecaller will boost their international expansion in their key markets in North America, Asia and the Middle East.
PEOPLE Truecaller is a global crowdsourced phone directory available on iPhone, Android, Symbian (S60 & S40), Blackberry, Windows Phone and on the web.
Truecaller has millions of users that currently perform more than 120 million searches each month and the user base increases rapidly. Turecaller’s users, from all over the world, share their phone books, including numbers to pre-paid phones, and together create a relevant global directory – users can easily opt-in or out at any time. Founded in Stockholm, Sweden, 2009 Truecaller is owned by the founder duo, angels and VC company Open Ocean.
AyoxxA Biosystems Closes Series A Financing Round
FUND AyoxxA Biosystems, an international biotechnology company, announces it has closed a 2.6 million Euro Series A financing round.
INVESTOR The round was led by Wellington Partners Venture Capital and included
NRW.BANK, HTGF - High-Tech Gründerfonds, and private investors, Rainer Christine and Dr. Gregor Siebenkotten.
TARGET The funds raised will be used to drive the further development of AyoxxA’s proprietary platform technology and the scale-up of production of its novel bead-based biochips as the company moves towards commercialization.
PEOPLE AyoxxA, an international biotech company based in Cologne, Germany, and Singapore, has developed a proprietary technology platform for multiplexed protein analysis. Core to this cutting-edge technology are “In-situ Encoded Bead-based Arrays” (IEBA) which allow simultaneous, precise and cost effective protein analysis in very small sample volumes.
These novel biochips allow users to combine high throughput screening and multiplexed assay formats at the same time and thus have the potential to revolutionize applications in biomedical research, pharmacological screening, and diagnostics.
Name AyoxxA Biosystems
Target To drive the further development of AyoxxA’s proprietary platform technology and scale-up production of its novel bead- based biochips
Investors Wellington Partners Venture Capital,
NRW.BANK, HTGF - High-Tech Gründerfonds
Private Investors Rainer Christine & Dr Gregor Siebenkotten
ContinuumRx, Inc. Closes $7 Million in Equity Financing
Name
ContinuumRx Target
Continued growth throughout the Southeastern U.S.
Investors
Mitsui & Co. Global Investment, Inc., Health Enterprise Partners, L.P. (HEP), Fidelis Capital Partners, Redmont Venture Partners and Stonehenge Capital Company
FUND ContinuumRx announces that it has closed on $7 Million in new financing.
INVESTOR The financing was led by Mitsui & Co. Global Investment, Inc.; Health Enterprise Partners, L.P. (HEP); and local investors, including Fidelis Capital Partners, Redmont Venture Partners, and Stonehenge Capital Company.
TARGET The new capital is to be used for continued growth throughout the southeastern U.S. "Securing this growth capital from quality investors is vital to our long-terms goals," said Chuck Jett, ContinuumRx's Chairman and CEO. "We signed our first joint
96
www.finance-monthly.com
venture agreement with the University of Tennessee Medical Center in November of 2010. Today, with our joint venture partners, we serve patients and physicians at eight major healthcare systems operating 30 hospitals and medical centers in Tennessee, Mississippi, and Alabama."
PEOPLE ContinuumRx is based in Birmingham, Alabama and develops joint ventures with market-leading health systems to seek to improve patient outcomes through better coordination in the hospital-to-home transition. Through its unique integrated model with health systems and their affiliated providers, ContinuumRx is creating a better model of care for patients with chronic and complex conditions.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112